StockNews.com Begins Coverage on Ekso Bionics (NASDAQ:EKSO)

StockNews.com started coverage on shares of Ekso Bionics (NASDAQ:EKSO) in a research note issued to investors on Thursday morning. The firm issued a hold rating on the stock.

Other equities research analysts have also issued reports about the stock. Lake Street Capital initiated coverage on shares of Ekso Bionics in a research note on Monday, June 24th. They set a buy rating and a $2.50 target price for the company. HC Wainwright restated a buy rating and set a $10.00 price target on shares of Ekso Bionics in a research note on Tuesday, July 30th.

Ekso Bionics Trading Up 3.9 %

NASDAQ:EKSO opened at $1.06 on Thursday. Ekso Bionics has a one year low of $0.74 and a one year high of $3.13. The company’s 50-day simple moving average is $1.09 and its 200 day simple moving average is $1.18. The firm has a market capitalization of $19.26 million, a P/E ratio of -1.09 and a beta of 1.45. The company has a debt-to-equity ratio of 0.36, a current ratio of 2.42 and a quick ratio of 1.77.

Ekso Bionics (NASDAQ:EKSO) last issued its earnings results on Monday, July 29th. The company reported ($0.13) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.11) by ($0.02). Ekso Bionics had a negative return on equity of 92.08% and a negative net margin of 68.41%. The firm had revenue of $4.95 million during the quarter, compared to the consensus estimate of $5.34 million. During the same quarter in the prior year, the company posted ($0.31) EPS. As a group, analysts forecast that Ekso Bionics will post -0.42 EPS for the current fiscal year.

Institutional Inflows and Outflows

An institutional investor recently raised its position in Ekso Bionics stock. Kent Lake Capital LLC raised its position in shares of Ekso Bionics Holdings, Inc. (NASDAQ:EKSO) by 322.3% during the 1st quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 596,050 shares of the company’s stock after purchasing an additional 454,892 shares during the quarter. Kent Lake Capital LLC owned 3.28% of Ekso Bionics worth $811,000 as of its most recent SEC filing. 6.42% of the stock is currently owned by hedge funds and other institutional investors.

About Ekso Bionics

Ekso Bionics Holdings, Inc designs, develops, sells, and rents exoskeleton products in the Americas, Germany, Poland, Europe, the Middle East, Africa, the Asia Pacific, and internationally. It operates in two segments, EksoHealth and EksoWorks. The EksoHealth segment designs, engineers, manufactures, and markets exoskeletons for applications in the medical markets.